ThirtyFiveBio
Shelley Cook is currently working as the Chief Operating Officer at M:M Bio, Pathios Therapeutics, and ThirtyFiveBio. Before their current roles, Shelley held positions such as Director at GS2 Consultants Ltd, Head Of Operations and Alliance Manager at Sitryx, Business Operations Manager at Immunocore, Consultant Healthcare Analyst at Peel Hunt, Postdoctoral Researcher at the Natural History Museum, and Sir Henry Wellcome Postdoctoral Fellow at the Wellcome Trust. Shelley holds a Ph.D. in Emerging Tropical Viruses, a Master's Degree in Integrative Bioscience, and a Bachelor's Degree in Biology/Biological Sciences.
ThirtyFiveBio
ThirtyFiveBio is an early-stage drug discovery company that was established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of GPR35. We are currently engaged in a fully enabled drug discovery program to identify novel small-molecule modulators of GPR35